{"id":"W2922249564","doi":"10.1182/blood-2019-01-896290","title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; Cancer Research UK; F. Hoffmann-La Roche","keywords":"Venetoclax; Obinutuzumab; Chronic lymphocytic leukemia; Medicine; Refractory (planetary science); Fludarabine; Leukemia; Bendamustine; Ibrutinib; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004144475,0.0002942917,0.0008061907,0.00033964,0.00003579034,0.00001905231,0.0002150575,0.0002045267,0.0001758946],"category_scores_gemma":[0.0001522344,0.0002618417,0.00007710847,0.0005502464,0.0001240992,0.000120724,0.0001708247,0.0003490743,0.0001143372],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.09242295,"about_ca_system_score_gemma":0.04607147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006019695,"about_ca_topic_score_gemma":0.0004526749,"domain_scores_codex":[0.9973672,0.0001459808,0.0006328814,0.0006260804,0.0006098542,0.0006180081],"domain_scores_gemma":[0.9983363,0.0002209866,0.0001651814,0.0009333384,0.0001075189,0.000236749],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04704834,0.1192093,0.1815188,0.03251955,0.01168044,0.0280707,0.08115213,0.009836788,0.3806476,0.0005984405,0.003102003,0.1046159],"study_design_scores_gemma":[0.9199147,0.02527563,0.005647874,0.001196765,0.0007292755,0.0008096516,0.001273485,0.03009886,0.01390113,0.00002725519,0.0006191165,0.0005063355],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927392,0.003359733,5.433848e-7,0.000005401757,0.00007667455,0.002532637,0.000005940245,0.00006914798,0.001210736],"genre_scores_gemma":[0.9980273,0.0003568352,0.00002821494,0.00002543954,0.00008979321,0.00007999541,0.00002285796,0.00006310392,0.001306476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8728663,"threshold_uncertainty_score":0.9999834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01331729804762806,"score_gpt":0.29284353042943,"score_spread":0.2795262323818019,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}